Real-World study checks how well oral semaglutide controls diabetes

NCT ID NCT05443191

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 50 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over about 8-10 months. Participants also filled out a questionnaire about how they took the medication. The goal was to see how well the drug works in everyday life, not in a controlled lab setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Rybelsus)
What this could lead to: If successful, this could confirm that oral semaglutide helps control blood sugar and weight in real-world settings, supporting its use for type 2 diabetes management.
What could go wrong: This is an observational study with only 50 participants, so results may not apply to everyone. It does not test new effects or compare with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Aava Lääkärikeskus Kamppi

Helsinki, 00100, Finland
Master Centre for Finland

Helsinki, Finland, 00100, Finland
Master centre for France_Paris La défense cedex

Paris, La Défense, cedex, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.